Hamilton and Bionano Genomics Announce Commercial Availability of World’s First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM
October 26 2022 - 8:00AM
Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) announced
today that the Long String VANTAGE, a system for automated, high
throughput isolation of ultra high molecular weight (UHMW) DNA for
use in optical genome mapping (OGM) is commercially available. The
Long String VANTAGE is the result of collaborative development from
the companies and features new and innovative tools and consumables
used for consistent, high-quality UHMW DNA extraction using human
blood samples. The Long String VANTAGE is expected to begin
shipping in Q1 2023.
Since first announcing their collaboration at the European
Society of Human Genetics Conference in June 2022, the companies
have continued to test and refine their walk-away automation
solution for UHMW DNA extraction. Hamilton’s Long String Genomics
product program supports the extraction of UHMW DNA at increased
scale. Initial testing has been performed on cell lines and blood
samples, with bone marrow aspirates (BMA) and other sample types
expected soon. Results also confirmed that labs can process up to
12 UHMW DNA samples per run and 24 UHMW DNA samples with high
consistency and reproducibility in an eight-hour workday. The
automated workflow marks a significant improvement over the manual
method, dramatically reducing the hands-on time and the number of
samples that can be purified to UHMW DNA.
The companies continue to collaborate with select clinical
research laboratories to test and further develop applications with
different sample types for the use of the Long String VANTAGE and
the Bionano Prep SP kits. Ongoing developments will focus on the
automation of UHMW DNA extraction from BMA. Hamilton plans to start
taking orders for new solutions October 25, 2022. Bionano will
support orders with modified and automation ready versions of the
Bionano Prep SP reagent kits, and a modified compatible direct
label and stain (DLS) kit.
“We believe today marks an important day for anyone seeking to
implement OGM at scale, with the announcement of commercial
availability of the first automated solution for UMHW DNA
isolation. The analysis of UHMW DNA can provide a more thorough way
of detecting genomic aberrations that may be missed by traditional
cytogenetic methods. Bionano and Hamilton look forward to seeing
customers benefit from this solution in the coming months, which
can reduce time-to-results, reduce hands-on-time and improve OGM
performance by standardizing the process of UHMW DNA isolation,”
commented Erik Holmlin, PhD, president and chief executive
officer of Bionano Genomics.
About Hamilton
Hamilton is a leading global manufacturer, providing automated
liquid handling workstations and laboratory automation technology
to the scientific community. With a focus on innovative design,
Hamilton products incorporate patented liquid handling technologies
into a portfolio that includes liquid handling platforms, standard
application-based solutions, small devices, consumables, and OEM
liquid handling solutions. Known for advancing life science,
clinical diagnostics, forensics and biotechnology industries,
Hamilton products offer reliability, performance, and flexibility.
Ensuring a continuous commitment to quality, Hamilton utilizes
state-of-the-art manufacturing at production facilities in Reno,
Nevada and Bonaduz, Switzerland and has earned a global ISO 9001
certification. Privately held, Hamilton maintains headquarters in
Reno, Nevada; Franklin, Massachusetts; and Bonaduz, Switzerland,
along with subsidiary offices throughout the world.
www.hamiltoncompany.com/robotics
About Bionano Genomics, Inc.
Bionano Genomics is a provider of genome analysis solutions
that can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through
its Lineagen d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information,
visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “expect,” “plan,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the anticipated benefits and improvements resulting from the use of
Hamilton’s Long String VANTAGE, or the ability of that system to
reliably and consistently isolate high quality and sufficient
quantity of UHMW DNA for use with OGM. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements in existing technologies; failure of
the Long String VANTAGE to provide the anticipated benefits
described in this press release; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024